Clinical Trial Detail

NCT ID NCT03861403
Title A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Leap Therapeutics, Inc.

triple-receptor negative breast cancer

breast carcinoma

ovary epithelial cancer

Advanced Solid Tumor

fallopian tube cancer

prostate adenocarcinoma

peritoneum cancer


Avelumab + Cyclophosphamide + TRX518

Age Groups: adult senior

Additional content available in CKB BOOST